Cecilia H Marzabadi
Seton Hall University, USA
Posters & Accepted Abstracts: Eur J Exp Bio
The development of novel TLR4 agonists for use as immunomodulators and as adjuvants for vaccines is becoming increasingly important. TLR4 signaling occurs through both MyD88- dependent, as well as, MyD88-independent pathways, thus allowing for a robust immune response to the antigen. Achieving the proper balance between activation of different T-cell subtypes is the challenge in chemical modification of the structure of the agonist. Our efforts toward the synthesis and biological evaluation of novel carbohydrate structures that elicit immunomstimulatory responses will be presented.
Spanish 
Chinese 
Russian 
German 
French 
Japanese 
Portuguese 
Hindi 